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abstract
Keywords:

Among agents for opioid addiction treatment, methadone is a full m-opioid receptor agonist,

Buprenorphine

whereas buprenorphine is a partial agonist. Both are long-acting agents. Buprenorphine has

Medication-assisted treatment

a superior safety profile. Methadone is formulated for oral administration and buprenor-

Methadone

phine is formulated for sublingual administration. The U.S. Food and Drug Administration is

Opioid addiction

considering for approval a subdermal buprenorphine implant that has a six-month duration
of action. Both medications reduce mortality rates and improve other outcomes. Data from a
recent randomized, controlled comparison study (N ¼ 1269) of both medications show better
treatment retention with methadone, but reduced illicit opioid use early in treatment with
buprenorphine. Risk behaviors for human immunodeficiency virus (HIV) were measured by
using the Risk Behavior Survey at baseline, at 12 weeks, and at 24 weeks for study completers. In the 30 days prior to entering treatment, 14.4% of the completers (n ¼ 340) who were
randomized to treatment with buprenorphine had shared needles and 14.1% of the completers (n ¼ 391) who were randomized to methadone treatment had shared needles. In the
30 days prior to Week 24, the percentage of patients sharing needles decreased to 2.4% for the
buprenorphine group and 4.8% for the methadone group (p < 0.0001). In the 30 days prior to
entering treatment, 6.8% of the completers randomized to buprenorphine and 8.2% of the
completers randomized to methadone had multiple sexual partners; at Week 24, only 5.2%
and 5.1%, respectively, reported multiple partners (p < 0.04).
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. All rights reserved.

1.

Introduction

Most patients with opioid use disorder require pharmacotherapy for effective treatment. The most frequent medications

used in this treatment are methadone and buprenorphine. This
paper summarizes the basic pharmacology and clinical use of
these medications, and summarizes findings from a large,
open-label randomized controlled trial that compared the two
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medications in regard to liver health, treatment retention, and
changes in risk behavior.

2.
Methadone treatment for opioid use
disorder
Methadone absorption occurs rapidly after oral ingestion [1].
Methadone has a typical oral bioavailability of approximately
80% and a range of 41e95% [2]. The initial effects occur within
30 minutes; however, after ingestion, the peak effects and
peak plasma levels are attained on average at approximately 4
hours (range, 1e6 hours) [3]. Methadone has an average terminal half-life of 22 hours (range, 5e130 hours) [4].
Methadone metabolism is complex and not yet fully understood. Most available data indicate that the liver enzyme
CYP 450 3A4 is the primary catalyst of methadone metabolism
[5]. There is growing evidence that other enzymes such
as CYP2B6, CYP2D6, CYP1A2, CYP2C9, and CYP2C19 also
contribute to methadone metabolism [4,6]. These enzymes
exhibit wide inter-individual variation in activity, based primarily on genetics and on environmental factors; therefore,
every patient’s body metabolizes methadone a bit differently,
and the dosing must be individualized.
The long half-life of methadone makes it a highly effective
pharmacologic intervention for opioid use disorder. For most
patients, a once daily oral dose prevents opioid withdrawal
symptoms, which are a strong driver for ongoing illicit opioid
use. Finding the best dose for an individual patient often involves a clinical balancing act because the doses needed to
establish adequate tolerance while diminishing illicit opioid
can cause some side effects. Clinical trial evidence shows that
methadone doses of from 80e100 mg per day have significant
advantages, compared to lower doses, in reducing illicit opioid
use and in retaining patients in treatment [7]. For most patients, a stable dose ranges from 80e120 mg per day. However,
because of interindividual differences, some patients are able
to stabilize at a lower dose, whereas some patients need a
higher dose to stabilize.

3.
Burprenorphine treatment for opioid use
disorder
Buprenorphine has a unique and complex pharmacology;
however, one of its defining characteristicsd in contrast to
methadonedis its safety profile. Buprenorphine has poor oral
bioavailability. Therefore, in the formulations currently
approved for treating opioid use disorder, buprenorphine is
ingested via the sublingual route. As with methadone, its
gradual onset and long half-life contribute to its efficacy.
Buprenorphine acts as a partial agonist with a high affinity
for and slow dissociation at the m-opioid receptor, and it
functions as an antagonist at the k-opioid receptor [8,9].
Because buprenorphine is a partial m-opioid agonist, it has a
ceiling effect on m-opioid receptor activity so that, after
ingesting a modest dosage, further doses do not increase the
effects, and thus the risks of respiratory depression and
overdose are very low [10,11].

Currently marketed buprenorphine for treating opioid use
disorder comes in three sublingual formulations: (1) buprenorphine sublingual tablets; (2) buprenorphine/naloxone
sublingual tablets; and (3) buprenorphine/naloxone sublingual film. The buprenorphine/naloxone formulation is intended to prevent misuse of the medication by injection.
Naloxone, a m-opioid antagonist, has minimal sublingual
bioavailability. When the medication is administered by the
sublingual route, the amount of naloxone absorbed is too little
to have any clinically observable effect. However, because
naloxone has very good parenteral bioavailability, crushing
and injecting the buprenorphine/naloxone tablet results in
the simultaneous coadministration of a partial agonist and an
antagonist. Naloxone will reduce any parenteral effects of
buprenorphine and possibly precipitate opioid withdrawal if
full agonist opioids are present [12].
The buprenorphine-only tablets are supplied as 2-mg tablets and 8-mg tablets. The buprenorphine/naloxone tablets
are supplied as 2 mg buprenorphine/0.5 mg naloxone and
8 mg buprenorphine/2 mg naloxone. The buprenorphine/
naloxone film has two additional dosage forms: 4 mg buprenorphine/1 mg naloxone and 12 mg buprenorphine/2.5 mg
naloxone. An experimental formulation of buprenorphineda
subdermal implant that releases active medication over a 6month perioddis being studied, but it appears safe and efficacious [13].
The absorption of buprenorphine proceeds promptly after
its sublingual ingestion [14]. Sublingual bioavailability shows
large interindividual variability, but it is generally approximately 35% for the tablet [14e16]. The initial effects appear
within 30 minutes with peak effects and peak plasma levels
attained, on average, approximately 1 hour after ingestion
[14,17,18]. Buprenorphine has an estimated average terminal
half-life of 32 hours [14]; however, there is wide variation
across studies and individuals [19]. Buprenorphine undergoes
both glucuronidation and N-dealkylation. Most available data
indicate that N-dealkylation is catalyzed by the liver enzyme
CYP 450 3A4 [14]. A product of N-dealkylation is the active
metabolite, norbuprenorphine [14,18].
As a partial m-opioid agonist with high affinity for the receptor, buprenorphine may cause precipitated opioid withdrawal if administered when a full agonist occupies the
receptors because it can displace the full agonist and immediately reduce activation of the receptors [20]. To avoid the
risk of precipitated opioid withdrawal, induction on buprenorphine requires the patient to abstain from short-acting
opioids for approximately 24 hours and thereby enter a state
of moderate opioid withdrawal prior to the administration of
the first dose of buprenorphine. When the patient arrives for
induction, a physician must witness the presence of objective
signs of opioid withdrawal such as lacrimation, rhinorrhea,
yawning, sneezing, coughing, piloerection, restlessness, or
tremor. Induction can begin with a low buprenorphine dosage
of 2 mg or 4 mg. This first buprenorphine dosage will likely
ameliorate most of the withdrawal signs and symptoms
within 30e60 minutes. Once the withdrawal improvement
occurs, additional doses can be safely administered until any
lingering withdrawal symptoms resolve, usually within a day
or two at doses of 8e16 mg per day. Final stabilization doses of
buprenorphine range 2e32 mg per day.
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4.

Efficacy of opioid agonist medications

A buprenorphine study examining the efficacy of opioid
agonist medications randomly assigned 40 patients to a year’s
treatment with 16 mg per day or to a 6-day taper, followed by a
placebo. All patients received intensive behavioral interventions. Seventy-five percent of the buprenorphinetreated patients remained in treatment for 1 year, compared
to 0% of the placebo-treated patients. Seventy-five percent
of urine specimens collected from the buprenorphine-treated
patients were negative for illicit drugs. Four placebo-treated
patients died during the year versus none of the
buprenorphine-treated patients [21]. A similar controlled,
although not blinded, trial randomly assigned 34 heroin addicts to either a control group that offered psychosocial
treatment only or a methadone treatment group. The control
group had a mortality rate of 11.8% within 2 years, compared
to the 0% mortality rate in the methadone group [22].
Methadone and buprenorphine can produce many of the
side effects that are typical of opioid medications such as
sedation, nausea, constipation, weight gain, lowered libido,
edema, and headache. Methadone can also prolong the cardiac QT interval. Many side effects can be resolved or reduced
in severity by incremental dose reductions every 5e7 days of
methadone (by 5e10 mg) or of buprenorphine (2e4 mg).
A large open-label, randomized clinical trialdthe Starting
Treatment with Agonist Replacement Therapies (START) trial
(N ¼ 1269)dcompared buprenorphine/naloxone treatment to
methadone treatment, primarily in regard to their effects on
liver health, treatment retention, illicit substance use, and HIV
risk behavior [23]. This study was recently completed. After
providing baseline liver indices, the participants were
randomly assigned to receive either buprenorphine/naloxone
[at a mean maximum daily dose of 22.2 mg; standard deviation ( SD), 9.3] or methadone (at a mean maximum daily dose
of 93.2 mg; SD, 43.9) for 24 weeks. Repeat liver tests were obtained at Week 1, Week 2, Week 4, Week 8, Week 12, Week 16,
Week 20, and Week 24. Urine drug screens were obtained
weekly. Self-reported drug use data were collected every 4
weeks.
Participants were considered “evaluable” if they completed
24 weeks of medication and provided at least four blood
samples for postbaseline liver transaminase testing (n ¼ 340
for buprenorphine/naloxone and n ¼ 391 for methadone).
Changes in transaminase levels were not different between
the medication conditions. Baseline infection with hepatitis C
or hepatitis B was the only significant predictor as the transaminase level increased from low to elevated.
Seventy-four percent of patients on methadone treatment
completed 24 weeks of treatment versus 46% of patients on
buprenorphine/naloxone treatment (p < 0.01). When the
maximum dose reached 60 mg/day or more, the completion
rate among the methadone patients increased to 80%. Thirty
percent of patients on buprenorphine/naloxone treatment
dropped out within 30 days of starting treatment, and the
completion rate increased linearly with dose with 60% of patients who took higher doses (30e32 mg/day) completing the
treatment [24]. During the first 9 weeks of treatment, positive
opiate urine results of the patients remaining in treatment
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were significantly lower among patients taking buprenorphine/naloxone than among patients taking methadone.
Higher medication doses were associated with lower rates of
illicit opiate use with both medications, but more so among
the buprenorphine/naloxone patients.
The risk behaviors were assessed at baseline, Week 12, and
Week 24 for the study completers. In the 30 days prior to
entering treatment, 14.4% of the evaluable participants who
were randomized to buprenorphine/naloxone and 14.1% of
the evaluable participants who were randomized to methadone (n ¼ 391) shared needles. In the 30 days prior to Week 24,
the proportion of patients sharing needles decreased to 2.4%
for the buprenorphine/naloxone group and 4.8% for the
methadone group (p < 0.0001). In the 30 days prior to entering
treatment, 6.8% of the completers randomized to buprenorphine/naloxone and 8.2% of the completers randomized to
methadone had multiple sexual partners. At Week 24, only
5.2% and 5.1%, respectively, reported multiple partners
(p < 0.05).
In summary, methadone and buprenorphine are both
highly effective and relatively well-tolerated treatments for
opioid use disorder, when provided in adequate doses.
Buprenorphine has a lower risk for overdose, but methadone
seems to retain patients in treatment longer. Both agents help
reduce HIV risk behaviors.
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